Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04427293 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Name: Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) — clinical trial record (NCT04427293)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorUniversity of Illinois at Chicago

Started2020-07-09

View on ClinicalTrials.gov ↗

This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery

Amendment history 3 changes detected by DataLookout

2026-08-29

Enrollment closed, study ongoing

2026-08-29

Primary completion pushed: 2026-07 → 2027-07

2026-08-29

Completion pushed: 2026-07 → 2027-07

Trial Details

NCT Number	NCT04427293
Lead Sponsor	University of Illinois at Chicago
Conditions	Triple Negative Breast Cancer
Enrollment	12 participants
Start Date	2020-07-09
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-28